Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alpha Tau Medical Ltd (DRTS)
USD12.34
+0.16 (+1.34%)
IL NASDAQ Healthcare Medical - Equipment & Services
Address
Kiryat HaMada St. 5 9777605
Jerusalem, IL
Jerusalem, IL
CEO
Uzi Sofer
Website
alphatau.com
IPO
2021-03-08
CIK 1871321 ISIN IL0011839383
Also trades on
NASDAQ Capital Market · DRTS (USD)
NASDAQ Global Market · DRTSW (USD)
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
News Sentiment (7d)
Based on only 1 article — low confidence
- New Strong Sell Stocks for July 7th Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.34
+0.16 (+1.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
757.5K
Beta
1.20
Float Shares
59.23M
Free Float %
67.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.48% | +10.90% | +33.00% | +47.51% | +190.22% | +115.76% | +244.52% | +197.49% | +10.22% | +5.74% | +5.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
12.34
Low
8.00
-35.2%
Consensus
11.50
-6.8%
Median
11.50
-6.8%
High
15.00
+21.5%
DCF (Levered)
0.03
-99.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
11.50
-6.8%
|
| Last Quarter | 3 |
11.67
-5.5%
|
| Last Year | 4 |
11.00
-10.9%
|
| All Time | 6 |
10.50
-14.9%
|
Quality scores
Altman Z-Score
10.09
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Equipment & Services: +14.1%—
-
EPS growth Medical - Equipment & Services: +15.4%-17.8% Q1'26: -116.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Equipment & Services: -3.5%—
-
EBIT margin Medical - Equipment & Services: +1.1%—
-
ROIC Medical - Equipment & Services: +2.4%-303.8% Q1'26: -1,535.7% (vs Q1'25)
-
Share dilution Medical - Equipment & Services: -2.1%+15.2% Q1'26: +27.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Equipment & Services: 0.31×-0.33× Q1'26: -0.27× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 212.5K (-100.0%)
|
—
est: 325.0K (-100.0%)
|
1.23M
804.3K – 1.84M
+277.8% YoY
|
16.52M
10.82M – 24.72M
+1,245.3% YoY
|
72.94M
72.64M – 73.24M
+341.6% YoY
|
142.74M
93.51M – 213.62M
+95.7% YoY
|
259.02M
169.68M – 387.63M
+81.5% YoY
|
| EBITDA |
-30.30M
|
-41.06M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-31.40M
|
-42.29M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-31.75M
est: -36.26M (+12.4%)
|
-42.63M
est: -41.13M (-3.7%)
|
-46.93M
-49.75M – -45.06M
-14.1% YoY
|
-36.74M
-41.22M – -32.26M
+21.7% YoY
|
-2.53M
-4.16M – -1.40M
+93.1% YoY
|
24.58M
13.56M – 40.44M
+1,071.6% YoY
|
80.58M
44.45M – 132.60M
+227.9% YoY
|
| SGA |
7.92M
|
10.22M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.45
est: -0.45 (+0.0%)
|
-0.53
est: -0.51 (-3.8%)
|
-0.58
-0.62 – -0.56
-14.1% YoY
|
-0.46
-0.51 – -0.40
+21.7% YoY
|
-0.03
-0.05 – -0.02
+93.1% YoY
|
0.31
0.17 – 0.50
+1,071.6% YoY
|
1.00
0.55 – 1.65
+227.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-19 | Piper Sandler | Neutral | Neutral | Maintain |
| 2026-05-12 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
22
Total invested
16.42M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
22
-13 vs prev Q
New positions
6
Closed positions
20
Increased
9
Reduced
4
Put/Call ratio
0.00
Calls held
27.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 151.2K +151.2K (+100.0%) | 748.57M +748.6M (+100.0%) | 0.18% +0.181 pp | 0.58% +0.582 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 2 | HIGHTOWER ADVISORS, LLC | 686.6K +— (+0.0%) | 3.40M +302.1K (+9.8%) | 0.82% -0.035 pp | 0.00% +0.000 pp | USD3.07 +61.2% | 9 qtrs — |
| 3 | APELLA CAPITAL, LLC | 382.3K +382.3K (+100.0%) | 1.89M +1.9M (+100.0%) | 0.46% +0.456 pp | 0.04% +0.037 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 4 | LEVIN CAPITAL STRATEGIES, L.P. | 182.2K -22.5K (-11.0%) | 902.0K -21.2K (-2.3%) | 0.22% -0.037 pp | 0.08% -0.006 pp | USD3.24 +52.8% | 11 qtrs — |
| 5 | KOVITZ INVESTMENT GROUP PARTNERS, LLC | 157.9K -45.4K (-22.3%) | 781.4K -135.2K (-14.7%) | 0.19% -0.064 pp | 0.02% +0.014 pp | USD2.56 +93.4% | 8 qtrs — |
| 6 | MARINER, LLC | 125.2K +1.9K (+1.6%) | 619.6K +63.7K (+11.5%) | 0.15% -0.004 pp | 0.00% +0.000 pp | USD3.99 +24.1% | 9 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 107.8K +70.1K (+185.7%) | 533.7K +363.5K (+213.6%) | 0.13% +0.082 pp | 0.00% +0.000 pp | USD4.80 +3.1% | 2 qtrs — |
| 8 | SATOVSKY ASSET MANAGEMENT LLC | 53.6K +— (+0.0%) | 265.4K +23.6K (+9.8%) | 0.06% -0.003 pp | 0.05% +0.003 pp | USD2.97 +66.7% | 9 qtrs — |
| 9 | PRIVATE ADVISOR GROUP, LLC | 47.6K +— (+0.0%) | 235.5K +20.9K (+9.8%) | 0.06% -0.002 pp | 0.00% +0.000 pp | USD3.01 +64.5% | 9 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 44.1K +21.7K (+96.6%) | 218.5K +117.2K (+115.7%) | 0.05% +0.025 pp | 0.00% +0.000 pp | USD4.70 +5.3% | 13 qtrs — |
| 11 | SUMMIT FINANCIAL, LLC | 44.0K -7.6K (-14.7%) | 218.0K -14.7K (-6.3%) | 0.05% -0.012 pp | 0.00% 0.000 pp | USD4.51 +9.8% | 2 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 37.9K +— (+0.0%) | 187.6K +16.7K (+9.8%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD6.48 -23.6% | 15 qtrs — |
| 13 | NORTHERN TRUST CORP | 33.7K +— (+0.0%) | 167.0K +14.8K (+9.8%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD3.06 +61.8% | 9 qtrs — |
| 14 | COLONY GROUP, LLC | 32.3K +32.3K (+100.0%) | 159.7K +159.7K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 15 | CITADEL ADVISORS LLC | 25.2K +25.2K (+100.0%) | 124.7K +124.7K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 16 | WELLS FARGO & COMPANY/MN | 23.5K +17.5K (+291.7%) | 116.3K +89.3K (+329.9%) | 0.03% +0.021 pp | 0.00% +0.000 pp | USD4.69 +5.5% | 3 qtrs — |
| 17 | APTUS CAPITAL ADVISORS, LLC | 21.9K +— (+0.0%) | 108.6K +9.7K (+9.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD2.74 +80.7% | 8 qtrs — |
| 18 | FINANCIAL GUIDANCE GROUP, INC. | 21.9K +— (+0.0%) | 108.6K +9.7K (+9.8%) | 0.03% -0.001 pp | 0.04% +0.000 pp | USD4.12 +20.1% | 14 qtrs — |
| 19 | UBS GROUP AG | 20.7K -9.9K (-32.4%) | 102.5K -35.6K (-25.8%) | 0.02% -0.013 pp | 0.00% +0.000 pp | USD2.52 +96.4% | 8 qtrs — |
| 20 | QUENT CAPITAL, LLC | 20.0K +20.0K (+100.0%) | 99.0K +99.0K (+100.0%) | 0.02% +0.024 pp | 0.01% +0.007 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 21 | MORGAN STANLEY | 19.1K -30.9K (-61.8%) | 94.6K -130.9K (-58.1%) | 0.02% -0.039 pp | 0.00% +0.000 pp | USD3.63 +36.4% | 16 qtrs — |
| 22 | OPAL WEALTH ADVISORS, LLC | 10.0K +— (+0.0%) | 49.5K +4.4K (+9.8%) | 0.01% -0.001 pp | 0.01% +0.000 pp | USD3.18 +55.7% | 13 qtrs — |
| 23 | EQUITABLE HOLDINGS, INC. | 10.0K +— (+0.0%) | 49.5K +4.4K (+9.8%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.51 +97.2% | 4 qtrs — |
| 24 | TRIFECTA CAPITAL ADVISORS, LLC | 9.7K +9.7K (+100.0%) | 48.0K +48.0K (+100.0%) | 0.01% +0.012 pp | 0.01% +0.007 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 25 | TOWER VIEW INVESTMENT MANAGEMENT & RESEARCH LLC | 5.6K +— (+0.0%) | 27.6K +2.4K (+9.8%) | 0.01% 0.000 pp | 0.01% +0.001 pp | USD5.84 -15.2% | 14 qtrs — |
| 26 | BESSEMER GROUP INC | 3.7K +— (+0.0%) | 18.0K +1.0K (+5.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.51 +97.2% | 4 qtrs — |
| 27 | ALTSHULER SHAHAM LTD | 3.6K +1.8K (+100.0%) | 17.8K +9.7K (+119.5%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD4.73 +4.7% | 2 qtrs — |
| 28 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 3.3K +— (+0.0%) | 16.3K +1.5K (+9.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.87 +72.5% | 12 qtrs — |
| 29 | TD WATERHOUSE CANADA INC. | 2.6K +— (+0.0%) | 12.6K +1.5K (+13.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.51 +9.8% | 2 qtrs — |
| 30 | CITIGROUP INC | 1.5K +1.5K (+100.0%) | 7.4K +7.4K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 31 | CAITLIN JOHN, LLC | 1.5K +1.5K (+100.0%) | 7.4K +7.4K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.005 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 32 | SIMPLEX TRADING, LLC | 911.00 +911.0 (+100.0%) | 4.5K +4.5K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.95 +0.0% | 1 qtrs NEW |
| 33 | ADVISOR GROUP HOLDINGS, INC. | 515.00 -220.0 (-29.9%) | 2.5K -713.0 (-21.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.22 +53.7% | 7 qtrs — |
| 34 | JONES FINANCIAL COMPANIES LLLP | 225.00 -775.0 (-77.5%) | 1.1K -3.1K (-73.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.51 +9.8% | 2 qtrs — |
| 35 | GOLDMAN SACHS GROUP INC | — -12.3K (-100.0%) | — -55.5K (-100.0%) | 0.00% -0.015 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 36 | ENVESTNET ASSET MANAGEMENT INC | — -13.8K (-100.0%) | — -62.1K (-100.0%) | 0.00% -0.017 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 37 | RENAISSANCE TECHNOLOGIES LLC | — -61.9K (-100.0%) | — -279.2K (-100.0%) | 0.00% -0.077 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
| 38 | XTX TOPCO LTD | — -12.3K (-100.0%) | — -55.6K (-100.0%) | 0.00% -0.015 pp | 0.00% -0.003 pp | USD— | 4 qtrs SOLD |
| 39 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -5.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Levy Raphi | Officer | — | — | Options | 158,882 | 6.41 | 1.02M | 0 | D | ↗ |
| 2026-03-18 | Sofer Uzi | Director / Officer | — | — | Options | 396,680 | 7.32 | 2.90M | 0 | D | ↗ |
| 2026-03-18 | Netser Maya | Director | — | — | Restricted Share Units | 0 | 0.00 | — | 4,321 | D | ↗ |
| 2026-03-18 | MILCH DAVID MARK | Director | — | — | Options | 15,527 | 6.41 | 99.5K | 0 | D | ↗ |
| 2026-03-18 | Levy Raphi | Officer | — | — | Restricted Share Units | 0 | 0.00 | — | 54,433 | D | ↗ |
| 2026-03-18 | KIDRON NADAV | Director | — | — | Options | 15,527 | 6.41 | 99.5K | 0 | D | ↗ |
| 2026-03-18 | Blumenfeld S Morry | Director | — | — | Restricted Share Units | 0 | 0.00 | — | 4,680 | D | ↗ |
| 2026-03-18 | Avruch Michael | Director | — | — | Options | 15,527 | 6.41 | 99.5K | 0 | D | ↗ |
| 2026-03-18 | Alon Ruth | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 29,367 | D | ↗ |
| 2026-03-18 | Adler Alan | Director | — | — | Options | 15,527 | 6.41 | 99.5K | 0 | D | ↗ |
| 2025-06-17 | Sofer Uzi | Director / Officer | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-17 | MILCH DAVID MARK | Director | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-17 | Blumenfeld S Morry | Director | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-17 | Avruch Michael | Director | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-17 | Alon Ruth | Director | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-17 | Adler Alan | Director | — | — | Options | 24,460 | 4.05 | 99.1K | 0 | D | ↗ |
| 2025-06-12 | KIDRON NADAV | Director | — | — | Options | 35,554 | 2.79 | 99.2K | 0 | D | ↗ |
| 2025-04-01 | Sofer Uzi | Director / Officer | — | — | Options | 674,238 | 3.07 | 2.07M | 0 | D | ↗ |
| 2025-04-01 | Levy Raphi | Officer | — | — | Options | 267,641 | 2.60 | 695.9K | 0 | D | ↗ |
| 2025-01-17 | Netser Maya | Director | — | — | Options | 24,048 | 4.05 | 97.4K | 0 | D | ↗ |
| 2024-12-17 | Sofer Uzi | Director / Officer | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-12-17 | MILCH DAVID MARK | Director | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-12-17 | Blumenfeld S Morry | Director | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-12-17 | Avruch Michael | Director | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-12-17 | Alon Ruth | Director | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-12-17 | Adler Alan | Director | — | — | Options | 43,257 | 2.98 | 128.9K | 0 | D | ↗ |
| 2024-04-01 | Sofer Uzi | Director / Officer | — | — | Options | 763,843 | 3.48 | 2.66M | 0 | D | ↗ |
| 2024-04-01 | Levy Raphi | Officer | — | — | Options | 301,880 | 2.98 | 899.6K | 0 | D | ↗ |
| 2024-01-01 | Sofer Uzi | Director / Officer | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2024-01-01 | Blumenfeld S Morry | Director | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2024-01-01 | Avruch Michael | Director | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2024-01-01 | Adler Alan | Director | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2023-11-01 | MILCH DAVID MARK | Director | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2023-11-01 | Alon Ruth | Director | — | — | Options | 46,905 | 3.28 | 153.8K | 0 | D | ↗ |
| 2023-04-01 | Sofer Uzi | Director / Officer | — | — | Options | 1,102,653 | 3.57 | 3.94M | 0 | D | ↗ |
| 2023-04-01 | Levy Raphi | Officer | — | — | Options | 328,458 | 3.28 | 1.08M | 0 | D | ↗ |
| 2022-11-02 | Blumenfeld S Morry | Director | — | — | Options | 10,657 | 7.19 | 76.6K | 0 | D | ↗ |
| 2022-11-02 | Avruch Michael | Director | — | — | Options | 8,945 | 10.92 | 97.7K | 0 | D | ↗ |
| 2022-11-02 | Adler Alan | Director | — | — | Options | 10,657 | 7.19 | 76.6K | 0 | D | ↗ |
| 2022-06-07 | Sofer Uzi | Director / Officer | — | — | Options | 229,089 | 10.92 | 2.50M | 0 | D | ↗ |
| 2022-06-07 | Levy Raphi | Officer | — | — | Options | 80,360 | 7.19 | 577.8K | 0 | D | ↗ |
| 2022-06-07 | Blumenfeld S Morry | Director | — | — | Options | 24,727 | 11.50 | 284.4K | 0 | D | ↗ |
| 2022-06-07 | Avruch Michael | Director | — | — | Options | 24,727 | 11.50 | 284.4K | 0 | D | ↗ |
| 2022-06-07 | Adler Alan | Director | — | — | Options | 24,727 | 11.50 | 284.4K | 0 | D | ↗ |
| 2022-04-21 | Alon Ruth | Director | — | — | Options | 8,945 | 10.92 | 97.7K | 0 | D | ↗ |
| 2022-04-07 | MILCH DAVID MARK | Director | — | — | Options | 8,945 | 10.92 | 97.7K | 0 | D | ↗ |
| 2022-03-07 | Levy Raphi | Officer | — | — | Options | 90,529 | 4.03 | 364.8K | 0 | D | ↗ |
| 2020-09-03 | Levy Raphi | Officer | — | — | Options | 45,265 | 4.42 | 200.1K | 0 | D | ↗ |
| 2019-03-01 | Sofer Uzi | Director / Officer | — | — | Options | 54,318 | 4.42 | 240.1K | 0 | D | ↗ |
| 2019-03-01 | Blumenfeld S Morry | Director | — | — | Options | 54,318 | 4.42 | 240.1K | 0 | D | ↗ |
| 2019-03-01 | Avruch Michael | Director | — | — | Options | 54,318 | 4.42 | 240.1K | 0 | D | ↗ |
| 2019-03-01 | Adler Alan | Director | — | — | Options | 54,318 | 4.42 | 240.1K | 0 | D | ↗ |
| 2017-01-01 | Sofer Uzi | Director / Officer | — | — | Options | 54,318 | 1.10 | 59.7K | 0 | D | ↗ |
| 2017-01-01 | Avruch Michael | Director | — | — | Options | 54,318 | 1.10 | 59.7K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
88.01M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Uzi Sofer | Chief Executive Officer & Chairman | 1M | male |
| Raphi Levy | Chief Financial Officer | 763.0K | male |
| Robert Den | Chief Medical Officer & Member of Scientific Advisory Board | 756.0K | — |
| Ronen Segal | Chief Technology Officer | 435.0K | male |
| Amnon Gat | Chief Operations Officer | 251.0K | male |
| Rebecca Becker | Vice President of legal | — | female |
| Yael Zeiger | Corporate Controller | — | female |
| Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DRTS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
